Anti-RSV immunogens and methods of immunization

US8846056B2 · kind B2 · utility

Assignee

• The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control · US

Inventors

• Larry J. Anderson · Blue Springs, US
• Lia M. Haynes · Lithonia, US
• Ralph A. Tripp · Watkinsville, US

Key dates

• Filing date: Aug 4, 2010
• Grant date: Sep 30, 2014
• Expiry date: Dec 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.